Categories Earnings, Industrials

KB Home (NYSE: KBH) Q4 profit jumps 27% beats estimates

KB Home (NYSE: KBH) reported a 27% jump in earnings in the fourth quarter of 2019 helped by higher revenue as well as lower costs and expenses. The bottom line exceeded analysts’ expectations while the top line missed consensus estimates.

Net income jumped by 27% to $123.2 million or $1.31 per share. Revenue grew by 16% to $1.56 billion. The results were beneficial by the net order growth and housing gross profit margin.

KB Home (KBH) Q4 2019 earnings review

The total pre-tax income grew by 28% to $165 million, which included a charge for the early extinguishment of debt. Excluding this charge, pretax income jumped by 33% to $171.8 million.

Homes delivered increased 16% to 3,929 while the average selling price declined slightly to $392,500. Net orders for the quarter increased 38% to 2,777, with net order value up 43% to $1.06 billion. The strong demand for built-to-order products along with limited inventory in served markets drove net order higher by 38%.

The net orders growth was backed by a rise in community absorption pace to 3.7 net orders per month, its highest fourth-quarter pace in many years, along with a 9% growth in community count.

The average community count for the quarter increased 9% to 253. Ending community count grew 5% to 251. The cancellation rate as a percentage of gross orders improved to 22% for the quarter from 28%.

Read: Best China stocks to watch in 2020

The company’s ending backlog rose 24% to 5,078 homes. The ending backlog value grew to $1.81 billion, up 26% from $1.43 billion, with increases in all four regions.

As of November 30, 2019, the company had total liquidity of $1.23 billion, while notes payable stood at $1.75 billion. The debt to capital ratio improved by 740 basis points to 42.3% while the net debt to capital ratio is at 35.2%.

We’re on Flipboard! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top